Oxford Biomedica (LON:OXB) Shares Up 13.6% – Should You Buy?

Oxford Biomedica plc (LON:OXB) shares shot up 13.6% on Thursday . The company traded as high as GBX 920 and last traded at GBX 913.51. 1,679,148 shares changed hands during mid-day trading, an increase of 134% from the average session volume of 718,745 shares. The stock had previously closed at GBX 804.

Wall Street Analyst Weigh In

A number of research firms have commented on OXB. Canaccord Genuity Group reaffirmed a “buy” rating and set a GBX 451 price objective on shares of Oxford Biomedica in a research report on Tuesday, October 7th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the stock a “buy” rating in a research note on Friday, January 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Oxford Biomedica has an average rating of “Moderate Buy” and an average price target of GBX 606.40.

Oxford Biomedica Stock Down 1.5%

The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. The stock has a market cap of £1.09 billion, a P/E ratio of -24.82 and a beta of 1.09. The firm has a 50-day simple moving average of GBX 643.28 and a two-hundred day simple moving average of GBX 564.49.

Insider Activity at Oxford Biomedica

In other Oxford Biomedica news, insider Heather Preston purchased 6,175 shares of the stock in a transaction that occurred on Monday, October 20th. The shares were acquired at an average cost of GBX 593 per share, with a total value of £36,617.75. Company insiders own 34.83% of the company’s stock.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.